This listing of Claims will replace all prior versions, and listings, of Claims in the application:

Listing of Claims:

Claims 1-36 (canceled)

Claim 37 (new): A composition of matter for the transdermal administration of fenoldopam comprising:

(a) 5 to 50 weight % of fenoldopam;

(b) 5 to 40 weight % of a permeation enhancer; and

(c) 30 to 90 weight % of a polymeric carrier.

Claim 38 (new): A composition according to Claim 37 comprising a pharmaceutically acceptable salt of fenoldopam.

Claim 39 (new): A composition according to Claim 38 wherein the salt is fenoldopam mesylate.

Claim 40 (new): A composition according to Claim 39 wherein the permeation enhancer comprises myristyl sarcosine.

Claim 41 (new): A composition according to Claim 37 wherein the permeation enhancer comprises a monoglyceride.

Claim 42 (new): A composition according to Claim 41 further comprising a cosolvent selected from the group consisting of fatty acid esters, caproyl lactylic acid, lauroyl lactylic acid, and dimethyl lauramide.

Claim 43 (new): A composition according to Claim 42 wherein the monoglyceride is glycerol monolaurate and the cosolvent is selected from the group consisting of dodecyl acetate, lauryl lactate, isopropyl myristate, ethyl palmitate, and methyl laurate.

Claim 44 (new): A composition according to Claim 37 comprising 5 to 50 weight % fenoldopam base and 5 to 40 weight % of a permeation enhancer comprising a monoglyceride and a fatty acid ester.

Claim 45 (new): A compositon according to Claim 37 wherein the pH is maintained below 5.5.

Claim 46 (new): A composition according to Claim 45 wherein the pH is maintained with the range of 2-4.5.

Claim 47 (new): A device for the transdermal administration of fenoldopam at a therapeutically effective rate, comprising:

(a) reservoir comprising

(i) 5 to 50 weight % of fenoldopam;

(ii) 5 to 40 weight % of a permeation enhancer; and

(iii) 30 to 90 weight % of a polymeric carrier;

(b) a backing behind the skin contacting-distal surface of the reservoir; and

(c) means for maintaining the reservoir in fenoldopam transmitting relation with, the skin.

Claim 48 (new): A device according to Claim 47 comprising a pharmaceutically acceptable salt of fenoldopam.

Claim 49 (new): A device according to Claim 48 wherein the salt comprises fenoldopam mesylate.

Claim 50 (new): A composition according to Claim 49 wherein the permeation enhancer comprises myristyl sarcosine.

Claim 51 (new): A device according to Claim 47 wherein the permeation enhancer comprises a monoglyceride.

Claim 52 (new): A device according to Claim 51 further comprising a cosolvent selected from the group consisting of fatty acid esters, caproyl lactylic acid, lauroyl lactylic acid, and dimethyl lauramide.

Claim 53 (new): A device according to Claim 52 wherein the monoglyceride is glycerol monolaurate and the cosolvent is selected from the group consisting of dodecyl acetate, lauryl lactate, ethyl palmitate, isopropyl myristate, and methyl laurate.

Claim 54 (new): A device according to Claim 47 comprising 5 to 50 weight % fenoldopam base and 5 to 40 weight % of a permeation enhancer comprising a monoglyceride and a fatty acid ester.

Claim 55 (new): A device according to Claim 47 wherein the reservoir comprises a pressure sensitive adhesive which further acts as said means for maintaining the reservoir in fenoldopam transmitting relation with a body surface or membrane.

Claim 56 (new): A method for treating an individual in need of fenoldopam therapy comprising transdermally administering a fenoldopam composition to the individual during an administration period, said composition comprising:

(a) 5 to 50 weight % of fenoldopam;

(b) 5 to 40 weight % of a permeation enhancer; and

(d) 30 to 90 weight % of a polymeric carrier.

Claim 57 (new): A method according to Claim 56 wherein 1-6 mg/day of fenoldopam are administered.

Claim 58 (new): A method according to Claim 57 wherein 2-3 mg/day of fenoldopam are administered.

Claim 59 (new): A method according to Claim 58 for the treatment of acute renal failure.

Claim 60 (new): A method according to Claim 58 for the treatment of chronic renal failure.

Claim 61 (new): A method according to Claim 56 wherein fenoldopam is administered at a rate of 20-5500 .mu.g/hr.

Claim 62 (new): A method according to Claim 61 wherein fenoldopam is administered at a rate of 60-600 .mu.g/hr.

Claim 63 (new): A method according to Claim 62 wherein the administration period is 24-72 hours.

Claim 64 (new): A method according to Claim 56 wherein a pharmaceutically acceptable salt of fenoldopam is administered.

Claim 65 (new): A method according to Claim 64 wherein the salt comprises fenoldopam mesylate.

Claim 66 (new): A method according to Claim 56 wherein the permeation enhancer comprises a surfactant sarcosine.

Claim 67 (new): A method according to Claim 66 wherein the permeation enhancer comprises myristyl sarcosine.

Claim 68 (new): A method according to Claim 56 wherein the permeation enhancer comprises a monoglyceride.

Claim 69 (new): A method according to Claim 68 further comprising a cosolvent selected from the group consisting of fatty acid esters, caproyl lactylic acid, lauroyl lactylic acid, and dimethyl lauramide.

Claim 70 (new): A method according to Claim 69 wherein the monoglyceride is glycerol monolaurate and the cosolvent is selected from the group consisting of dodecyl acetate, lauryl lactate, ethyl palmitate, isopropyl myristate, and methyl laurate.